Meeting
2021 ASCO Annual Meeting
Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.
Authors
Yazmin Odia
Miami Cancer Institute, Baptist Health South Florida, Miami, FL
Yazmin Odia , Ludimila Cavalcante , Howard Safran , Steven Francis Powell , Pamela N. Munster , Wen Wee Ma , Benedito A. Carneiro , Bruno R. Bastos , Francis J. Giles , Solmaz Sahebjam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03678883
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2051)
DOI
10.1200/JCO.2021.39.15_suppl.2051
Abstract #
2051
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Next-generation sequencing (NGS) for identifying actionable molecular alterations in patients with newly diagnosed and recurrent IDHwt-glioblastoma (GBM): A large mono-institutional experience.
First Author: Marta Padovan
First Author: Jue Wang
Poster
2014 Genitourinary Cancers Symposium
Molecular profiling of advanced refractory prostate cancer.
First Author: Rebecca A. Feldman
Poster
2021 ASCO Annual Meeting
Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.
First Author: Chul Kim